Opinion

Video

Clinical Findings of Elacestrant, an Oral SERD for ER+/HER2– Metastatic Breast Cancer

Panelists discuss the clinical findings of elacestrant, an oral selective estrogen receptor degrader (SERD), for the treatment of ER+/HER2– metastatic breast cancer.

Related Videos
5 experts are featured in this series
5 experts are featured in this series
Eric Winer, MD
2 expert is featured in this series.